CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- 4/A Derivatives Options or other derivatives
- 8-K Event Material agreement
- 424B5 Offering Prospectus
- 8-K Event Other events
- 4 Open-market sale EVP, Chief Scientific Officer sold 1,148 shares at $112.25 ($128,863)
- 4 Open-market sale EVP, Chief Medical Officer sold 1,051 shares at $112.24 ($117,964)
- 4 Open-market sale EVP, Chief Financial Officer sold 1,013 shares at $112.24 ($113,699)
- 4 Grant or award EVP, General Counsel acquired 20,697 shares (grant or award)
- 8-K Event Regulation FD disclosure · Other events
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 8-K Event Material agreement · Unregistered share sale · Regulation FD disclosure
Page 16 of 37 · 725 filings